Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Long-Term Investments (2016 - 2023)

Myriad Genetics has reported Long-Term Investments over the past 14 years, most recently at $6.2 million for Q2 2023.

  • Quarterly Long-Term Investments fell 92.1% to $6.2 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Jun 2023, down 92.1% year-over-year, with the annual reading at $54.8 million for FY2022, 7.12% down from the prior year.
  • Long-Term Investments was $6.2 million for Q2 2023 at Myriad Genetics, down from $30.4 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $78.5 million in Q2 2022 and troughed at $6.2 million in Q2 2023.
  • The 5-year median for Long-Term Investments is $45.2 million (2020), against an average of $42.8 million.
  • Year-over-year, Long-Term Investments soared 494.96% in 2022 and then tumbled 92.1% in 2023.
  • A 5-year view of Long-Term Investments shows it stood at $47.6 million in 2019, then plummeted by 55.88% to $21.0 million in 2020, then skyrocketed by 180.95% to $59.0 million in 2021, then dropped by 7.12% to $54.8 million in 2022, then crashed by 88.69% to $6.2 million in 2023.
  • Per Business Quant, the three most recent readings for MYGN's Long-Term Investments are $6.2 million (Q2 2023), $30.4 million (Q1 2023), and $54.8 million (Q4 2022).